A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) [omacetaxine mepesuccinate] Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia

Trial Profile

A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) [omacetaxine mepesuccinate] Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary)
  • Indications Acute promyelocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2007 Status change from recruiting to withdrawn prior to recruitment.
    • 06 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top